Status:
UNKNOWN
Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls
Lead Sponsor:
Kenya Medical Research Institute
Collaborating Sponsors:
University of Washington
Conditions:
HPV-Related Carcinoma
Eligibility:
All Genders
16-24 years
Brief Summary
In 2013, the Investigators enrolled a cohort of 180 HIV-1 infected adolescent girls and boys ages 9-14 years and administered three doses of the QHPV vaccine (NCT04711265). For this study, the Investi...
Detailed Description
Genital Human Papilloma Virus (HPV) infections occur rapidly after sexual debut, and immunosuppressed individuals are at greater risk for incident and persistent infection. HPV vaccine contains virus-...
Eligibility Criteria
Inclusion
- received three doses of the quadrivalent HPV vaccine and enrolled in the quadrivalent HPV vaccine safety and immunogenicity study (MISP 38406)
- participant consent or parental/guardian consent and participant assent for participants still \<18 years of age
- participants and guardians who consented to be contacted for further evaluation and participation in research and
- are willing to continue longer-term follow up.
Exclusion
- Did not participate in the quadrivalent HPV vaccine safety and immunogenicity study (MISP 38406)
- Not willing or able to provide written informed consent/assent to participate in the study
Key Trial Info
Start Date :
August 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT04920526
Start Date
August 1 2021
End Date
December 1 2022
Last Update
June 10 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.